EMA grants PRIME scheme access to Bluebird's Lentiglobin and Juno's JCAR-015 Sep. 22, 2016 No Comments
Phase III study of vepoloxamer in sickle cell disease does not meet primary efficacy endpoint Sep. 21, 2016 No Comments
Akari Therapeutics' coversin granted U.S. orphan status for paroxysmal nocturnal hemoglobinuria Sep. 12, 2016 No Comments
LentiGlobin enters phase III testing in patients with transfusion-dependent beta-thalassemia Sep. 9, 2016 No Comments
Sangamo's SB-FIX gene therapy granted FDA orphan drug designation for hemophilia B Sep. 8, 2016 No Comments
Bristol-Myers Squibb presents novel PAR-4 antagonists as promising antithrombotic agents Sep. 6, 2016 No Comments
RSS